Anjali Singh

The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for diabetes and obesity

Inventory replenishment, resilient demand for premium models and stronger exports helped India's leading two-wheeler manufacturers record healthy growth in May

CDSCO's move can lead to the formalisation of more than 35,000 skin clinics, stop the mushrooming of single-operator setups run by unqualified practitioners

The drugmaker said strong domestic branded generics and international business growth helped drive record EBITDA performance in FY26

Sanofi's AI-powered AccelRare platform aims to help doctors identify rare diseases faster and improve referrals to specialist treatment centres in India

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally advanced cutaneous squamous cell carcinoma

The tyre maker posted strong fourth-quarter earnings driven by robust demand and announced a phased capacity expansion amid rising domestic and export opportunities

Tyre and auto-component makers raise prices as raw material and energy inflation erodes margins

Parexel says India is evolving into a strategic innovation and clinical research hub as global pharmaceutical firms shift high-value functions and decision-making roles

Innovative medicines business crosses $1 billion milestone as company expands specialty pipeline and bets on Organon acquisition

The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable efficacy and safety to the innovator drug

The pharmaceutical company reported robust growth in domestic formulations and insulin franchise performance, while maintaining a strong EBITDA margin of 37 per cent

Credit rating agency says domestic two-wheeler wholesale volumes may grow 3-5% in FY27, while exports and electric vehicle demand continue to support the industry

HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal

NephroPlus posted a 74.6% jump in FY26 profit as higher dialysis volumes and rapid international expansion boosted revenue and margins

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Hospitals, diagnostics firms, and support groups are expanding cancer care into tier-2 and tier-3 cities as demand, screening and awareness rise beyond large metros

Harsh Goenka says the conglomerate is expanding remote work, limiting travel and accelerating electric mobility adoption amid West Asia tensions

KPMG report says government schemes, rising urban mobility demand and improving economics are accelerating growth in India's electric bus market

Drugmaker cites lower contribution from key US products, higher R&D investments and rising operating costs as Q4 FY26 profit declines sharply